Full Press Release Details
DUBLIN , Nov. 9, 2012 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) announced today that the company will participate in three upcoming investor conferences. A live webcast of each presentation may be accessed from the Investors section of the Jazz Pharmaceuticals website at www.jazzpharmaceuticals.com . The conferences and presentation times include:
An archived version of each webcast will be available for at least one week following each respective presentation on the Investors section of the company's website at www.jazzpharmaceuticals.com .
About Jazz Pharmaceuticals Jazz Pharmaceuticals plc is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing innovative products that address unmet medical needs. The company has a diverse portfolio of products in the areas of narcolepsy, oncology, pain and psychiatry. The company's U.S. marketed products in these areas include: Xyrem ® (sodium oxybate) oral solution, Erwinaze ® (asparaginase Erwinia chrysanthemi ), Prialt ® (ziconotide) intrathecal infusion, Luvox CR ® (fluvoxamine maleate), FazaClo ® (clozapine, USP) HD and FazaClo LD. Outside of the U.S., Jazz Pharmaceuticals also has a number of products marketed by its international division, EUSA Pharma.
SOURCE Jazz Pharmaceuticals plc